Vivos Therapeutics, Inc. has announced that its VidaSleep™ oral appliance, equipped with FDA-cleared Unilateral Bite Block technology, has received approval from the Centers for Medicare & Medicaid ...

LITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (VVOS), a leading medical device and technology company specializing in the development and commercialization of highly ...

Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model Vivos’ DNA appliance now ...

On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, which is used to treat moderate to severe obstructive sleep apnea (OSA) and ...

The MarketWatch News Department was not involved in the creation of this content. The company is addressing a critical gap in fibromyalgia treatment: undiagnosed obstructive sleep apnea (OSA). With up ...

LITTLETON, Colo., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for ...

The MarketWatch News Department was not involved in the creation of this content. Strongly linked to attention disorders like ADHD, untreated pediatric OSA can significantly impact a child's ...

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

LITTLETON, Colo., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on sleep ...

LITTLETON, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the ...